Clinical Trial Update: A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 study evaluating PF-04457845 on BOLD fMRI in post-traumatic stress disorder was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• PF-04457845

Snippet

Sponsor: Pfizer | Conditions: Post-Traumatic Stress Disorder | Phase 2 | Status: TERMINATED | Results posted: 2016-04-08